PDCD1 and cancer: Based on studies with B16 melanoma cells, which typically show resistance to PD-1 therapy, adding a PTPN2 inhibitor to anti-PD-1 regimens may help expand the pool of cancer patients responsive to checkpoint inhibition (88).